Gankyrin activates mTORC1 signaling by accelerating TSC2 degradation in colorectal cancer

Cancer Letters

Volumn 376, Issue 1, 2016, Pages 83-94

  Qin, Xiaoyu ^a   Wang, Xinxin ^a   Liu, Feng ^a   Morris, Laura E ^b   Wang, Xiaowen ^b   Jiang, Bin ^b   Zhang, Yanjie ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Colorectal cancer; Gankyrin; mTOR; TSC2

Indexed keywords

GANKYRIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RHEB PROTEIN; TUBERIN; UNCLASSIFIED DRUG; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; MULTIPROTEIN COMPLEX; NEUROPEPTIDE; PROTEASOME; PSMD10 PROTEIN, HUMAN; RHEB PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER GROWTH; CARCINOGENESIS; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN METABOLISM; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL PROLIFERATION; COLORECTAL TUMOR; ENZYME ACTIVATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; NUDE MOUSE; PATHOLOGY; PROGNOSIS; TIME FACTOR; TUMOR CELL LINE; TUMOR VOLUME; UPREGULATION; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; KAPLAN-MEIER ESTIMATE; MICE, INBRED BALB C; MICE, NUDE; MONOMERIC GTP-BINDING PROTEINS; MULTIPROTEIN COMPLEXES; NEOPLASM TRANSPLANTATION; NEUROPEPTIDES; PROGNOSIS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRANSFECTION; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 84961964725     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.03.013     Document Type: Article

References (36)

1. Dawson S., Higashitsuji H., Wilkinson A.J., Fujita J., Mayer R.J. Gankyrin: a new oncoprotein and regulator of pRb and p53. Trends Cell Biol 2006, 16(5):229-233.
2. Higashitsuji H., Itoh K., Nagao T., Dawson S., Nonoguchi K., Kido T., et al. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat. Med 2000, 6(1):96-99.
3. Higashitsuji H., Higashitsuji H., Itoh K., Sakurai T., Nagao T., Sumitomo Y., et al. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell 2005, 8(1):75-87.
4. Krzywda S., Brzozowski A.M., Higashitsuji H., Fujita J., Welchman R., Dawson S., et al. The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53. J. Biol. Chem 2004, 279(2):1541-1545.
5. International Agency for Research on Cancer, and World Health Organization GLOBOCAN: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012 2014, IARC.
6. Wang X.W., Zhang Y.J. Targeting mTOR network in colorectal cancer therapy. World J. Gastroenterol 2014, 20(15):4178-4188.
7. Zhang Y.J., Dai Q., Sun D.F., Xiong H., Tian X.Q., Gao F.H., et al. mTOR signaling pathway is a target for the treatment of colorectal cancer. Ann. Surg. Oncol 2009, 16(9):2617-2628.
8. Li Y., Corradetti M.N., Inoki K., Guan K.L. TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem. Sci 2004, 29(1):32-38.
9. Aspuria P.J., Tamanoi F. The Rheb family of GTP-binding proteins. Cell. Signal 2004, 16(10):1105-1112.
10. Durán R.V., Hall M.N. Regulation of TOR by small GTPases. EMBO Rep 2012, 13(2):121-128.
11. Gao B., Roux P.P. Translational control by oncogenic signaling pathways. Biochim. Biophys. Acta 2015, 1849(7):753-765.
12. Thomas J.D., Zhang Y.J., Wei Y.H., Cho J.H., Morris L.E., Wang H.Y., et al. Rab1A Is an mTORC1 activator and a colorectal oncogene. Cancer Cell 2014, 26(5):754-769.
13. Gupta J., Igea A., Papaioannou M., Lopez-Casas P., Llonch E., Hidalgo M., et al. Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors. Oncotarget 2015, 6(11):8539-8551.
14. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., et al. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67(3):1030-1037.
15. Stocker H., Radimerski T., Schindelholz B., Wittwer F., Belawat P., Daram P., et al. Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat. Cell Biol 2003, 5(6):559-565.
16. Yan L., Findlay G.M., Jones R., Procter J., Cao Y., Lamb R.F. Hyperactivation of mammalian target of rapamycin (mTOR) signaling by a gain-of-function mutant of the Rheb GTPase. J. Biol. Chem 2006, 281(29):19793-19797.
17. Inoki K., Li Y., Xu T., Guan K.L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003, 17(15):1829-1834.
18. Li Y., Inoki K., Guan K.L. Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity. Mol. Cell. Biol 2004, 24(18):7965-7975.
19. Sato T., Umetsu A., Tamanoi F. Characterization of the Rheb-mTOR signaling pathway in mammalian cells: constitutive active mutants of Rheb and mTOR. Methods Enzymol 2008, 438:307-320.
20. Chong-Kopera H., Inoki K., Li Y., Zhu T., Garcia-Gonzalo F.R., Rosa J.L., et al. TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase. J. Biol. Chem 2006, 281(13):8313-8316.
21. Hu J., Zacharek S., He Y.J., Lee H., Shumway S., Duronio R.J., et al. WD40 protein FBW5 promotes ubiquitination of tumor suppressor TSC2 by DDB1-CUL4-ROC1 ligase. Genes Dev 2008, 22(7):866-871.
22. Aparicio S., Hidalgo M., Kung A.L. Examining the utility of patient-derived xenograft mouse models. Nat. Rev. Cancer 2015, 15(5):311-316.
23. Wang X., Jiang B., Zhang Y. Gankyrin regulates cell signaling network. Tumour Biol 2016, 10.1007/s13277-016-4854-z.
24. Su B., Luo T., Zhu J., Fu J., Zhao X., Chen L., et al. Interleukin-1beta/Iinterleukin-1 receptor-associated kinase 1 inflammatory signaling contributes to persistent Gankyrin activation during hepatocarcinogenesis. Hepatology 2015, 61(2):585-597.
25. Song X., Wang J., Zheng T., Song R., Liang Y., Bhatta N., et al. LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway. Mol. Cancer 2013, 12(1):114.
26. Dong L.W., Yang G.Z., Pan Y.F., Chen Y., Tan Y.X., Dai R.Y., et al. The oncoprotein p28GANK establishes a positive feedback loop in beta-catenin signaling. Cell Res 2011, 21(8):1248-1261.
27. Fu J., Chen Y., Cao J., Luo T., Qian Y.W., Yang W., et al. p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1alpha pathways. Hepatology 2011, 53(1):181-192.
28. Zheng T., Hong X., Wang J., Pei T., Liang Y., Yin D., et al. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma. Hepatology 2014, 59(3):935-946.
29. Zhang J., Yang Y., Zhang Z., He Y., Liu Z., Yu Y., et al. Gankyrin plays an essential role in estrogen-driven and GPR30-mediated endometrial carcinoma cell proliferation via the PTEN/PI3K/AKT signaling pathway. Cancer Lett 2013, 339(2):279-287.
30. Man J.H., Liang B., Gu Y.X., Zhou T., Li A.L., Li T., et al. Gankyrin plays an essential role in Ras-induced tumorigenesis through regulation of the RhoA/ROCK pathway in mammalian cells. J. Clin. Invest 2010, 120(8):2829-2841.
31. Benvenuto G., Li S., Brown S.J., Braverman R., Vass W.C., Cheadle J.P., et al. The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 2000, 19(54):6306-6316.
32. Wang H.L., Chang N.C., Weng Y.H., Yeh T.H. XLID CUL4B mutants are defective in promoting TSC2 degradation and positively regulating mTOR signaling in neocortical neurons. Biochim. Biophys. Acta 2013, 1832(4):585-593.
33. Han S., Witt R.M., Santos T.M., Polizzano C., Sabatini B.L., Ramesh V. Pam (Protein associated with Myc) functions as an E3 ubiquitin ligase and regulates TSC/mTOR signaling. Cell. Signal 2008, 20(6):1084-1091.
34. Wang R.H., He J.P., Su M.L., Luo J., Xu M., Du X.D., et al. The orphan receptor TR3 participates in angiotensin II-induced cardiac hypertrophy by controlling mTOR signalling. EMBO Mol. Med 2013, 5(1):137-148.
35. Zheng L., Ding H., Lu Z., Li Y., Pan Y., Ning T., et al. E3 ubiquitin ligase E6AP-mediated TSC2 turnover in the presence and absence of HPV16 E6. Genes Cells 2008, 13(3):285-294.
36. Akeno N., Miller A.L., Ma X., Wikenheiser-Brokamp K.A. p53 suppresses carcinoma progression by inhibiting mTOR pathway activation. Oncogene 2015, 34(5):589-599.